Renaissance Technologies (RenTech)'s NRIX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 118,000 shares of Nurix Therapeutics, Inc. (NRIX) worth $1.83 M, representing 0.00% of the portfolio. First purchased in 2022-Q1, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in NRIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 162,900 shares. Largest reduction occurred in Q4 2024, reducing 246,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Nurix Therapeutics (NRIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nurix Therapeutics (NRIX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +118,000 | New Buy | 118,000 | $15.50 |
| Q4 2025 | -184,800 | Sold Out | 0 | $0.00 |
| Q3 2025 | +162,900 | Add 743.84% | 184,800 | $9.24 |
| Q2 2025 | -37,600 | Reduce 63.19% | 21,900 | $11.39 |
| Q1 2025 | +59,500 | New Buy | 59,500 | $11.88 |
| Q4 2024 | -246,400 | Sold Out | 0 | $0.00 |
| Q3 2024 | -77,600 | Reduce 23.95% | 246,400 | $22.47 |
| Q2 2024 | +144,700 | Add 80.70% | 324,000 | $20.87 |
| Q1 2024 | +64,100 | Add 55.64% | 179,300 | $14.70 |
| Q4 2023 | +88,400 | Add 329.85% | 115,200 | $10.32 |
| Q3 2023 | +26,800 | New Buy | 26,800 | $7.87 |
| Q2 2023 | -28,900 | Sold Out | 0 | $0.00 |
| Q1 2023 | -89,800 | Reduce 75.65% | 28,900 | $0.01 |
| Q4 2022 | +45,400 | Add 61.94% | 118,700 | $0.01 |
| Q3 2022 | -45,100 | Reduce 38.09% | 73,300 | $13.03 |
| Q2 2022 | +42,200 | Add 55.38% | 118,400 | $12.67 |
| Q1 2022 | +76,200 | New Buy | 76,200 | $14.02 |
Renaissance Technologies (RenTech)'s Nurix Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Nurix Therapeutics, Inc. (NRIX) in Q1 2022, acquiring 76,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Nurix Therapeutics, Inc. (NRIX) for 17 quarters since Q1 2022.
Renaissance Technologies (RenTech)'s largest addition to Nurix Therapeutics, Inc. (NRIX) was in Q3 2025, adding 184,800 shares worth $1.71 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 118,000 shares of Nurix Therapeutics, Inc. (NRIX), valued at approximately $1.83 M.
As of the Q1 2026 filing, Nurix Therapeutics, Inc. (NRIX) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Nurix Therapeutics, Inc. (NRIX) was 324,000 shares, as reported at the end of Q2 2024.